Recently though, the US Food and Drug Administration (FDA) has approved three radiomitigators to increase survival of patients with the haematopoietic presentation of ARS all of which are cytokines: granulocyte-colony stimulating factor (G-CSF), polyethylene glycolylated G-CSF, and recombinant granulocyte–macrophage colony stimulating factor (GM-CSF)4. This evidence concerns the gene CSF3 and Axenfeld-Rieger syndrome.